1. Home
  2. TVRD vs MYSE Comparison

TVRD vs MYSE Comparison

Compare TVRD & MYSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

SELL

Current Price

$1.09

Market Cap

15.7M

Sector

Health Care

ML Signal

SELL

Logo Myseum Inc.

MYSE

Myseum Inc.

SELL

Current Price

$1.02

Market Cap

14.2M

ML Signal

SELL

Company Overview

Basic Information
Metric
TVRD
MYSE
Founded
2017
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
15.7M
14.2M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
TVRD
MYSE
Price
$1.09
$1.02
Analyst Decision
Buy
Analyst Count
9
0
Target Price
★ $8.88
N/A
AVG Volume (30 Days)
★ 207.0K
20.6K
Earning Date
11-13-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 79.01
56.64
EPS
N/A
★ N/A
Revenue
★ $911,000.00
$550.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 959.30
26.15
52 Week Low
$0.77
$0.99
52 Week High
$5.69
$11.54

Technical Indicators

Market Signals
Indicator
TVRD
MYSE
Relative Strength Index (RSI) 50.87 27.60
Support Level $0.85 N/A
Resistance Level $2.02 $1.66
Average True Range (ATR) 0.17 0.13
MACD 0.05 -0.00
Stochastic Oscillator 41.46 11.57

Price Performance

Historical Comparison
TVRD
MYSE

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

About MYSE Myseum Inc.

Myseum.AI Inc is an integrate proprietary privacy-first artificial intelligence (AI) and social media technology company. The Company is developing privacy-first agentic localized AI agents to assist in managing personal media such as photos, videos and messages, while maintaining privacy.

Share on Social Networks: